Immune-mediated mechanisms in atherosclerosis: Prevention and treatment of clinical manifestations

Current Pharmaceutical Design

Volumn 13, Issue 36, 2007, Pages 3701-3710

  Niessner, A ^b   Goronzy, J J ^a   Weyand, C M ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Atherosclerosis; Cardiovascular disease; Immune mechanisms; Immunomodulatory therapies; Inflammation; Plaque

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIBIOTIC AGENT; ANTITHROMBOCYTIC AGENT; ANTIVIRUS AGENT; C REACTIVE PROTEIN; CD3 ANTIBODY; CLOPIDOGREL; CORTICOSTEROID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXYCYCLINE; GLITAZONE DERIVATIVE; HEAT SHOCK PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN M ANTIBODY; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; INFLUENZA VACCINE; MACROLIDE; OXIDIZED LOW DENSITY LIPOPROTEIN RECEPTOR; PEXELIZUMAB; PNEUMOCOCCUS VACCINE; PROTEINASE INHIBITOR; PROTON PUMP INHIBITOR; RAPAMYCIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNINDEXED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ACUTE CORONARY SYNDROME; ANTIBACTERIAL ACTIVITY; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BACTERIAL INFECTION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CHLAMYDOPHILA PNEUMONIAE; CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; DIABETES MELLITUS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; GINGIVITIS; HEART INFARCTION; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; IMMUNE DEFICIENCY; IMMUNOMODULATION; IMMUNOPATHOLOGY; LOW DRUG DOSE; PERIODONTAL DISEASE; PHYSICAL ACTIVITY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK REDUCTION; UNSPECIFIED SIDE EFFECT; VIRUS INFECTION;

ANTI-BACTERIAL AGENTS; ATHEROSCLEROSIS; AUTOANTIGENS; BACTERIAL VACCINES; CARDIOVASCULAR AGENTS; HEAT-SHOCK PROTEINS; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, NATURAL; IMMUNOLOGIC FACTORS; IMMUNOTHERAPY; INFLAMMATION; LIPOPROTEINS, LDL; VIRAL VACCINES;

EID: 37449001497     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161207783018626     Document Type: Review

References (150)

1. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352: 1685-95.
2. Libby P. Inflammation in atherosclerosis. Nature 2002; 420: 868-74.
3. van der Wal AC, Becker AE, van der Loos CM, Das PK. Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation 1994; 89: 36-44.
4. Niessner A, Sato K, Chaikof EL, Colmegna I, Goronzy JJ, Weyand CM. Pathogen-sensing plasmacytoid dendritic cells stimulate cyto-toxic T-cell function in the atherosclerotic plaque through interferon-alpha. Circulation 2006; 114: 2482-9.
5. Yilmaz A, Lochno M, Traeg F, Cicha I, Reiss C, Stumpf C, et al. Emergence of dendritic cells in rupture-prone regions of vulnerable carotid plaques. Atherosclerosis 2004; 176: 101-10.
6. Ma-Krupa W, Jeon MS, Spoerl S, Tedder TF, Goronzy JJ, Weyand CM. Activation of arterial wall dendritic cells and breakdown of self-tolerance in giant cell arteritis. J Exp Med 2004; 199 173-83.
7. Ott SJ, El Mokhtari NE, Musfeldt M, Hellmig S, Freitag S, Rehman A, et al. Detection of diverse bacterial signatures in atherosclerotic lesions of patients with coronary heart disease: Circulation 2006; 113: 929-37.
8. Shah PK. Link between infection and atherosclerosis: who are the culprits: viruses, bacteria, both, or neither? Circulation 2001; 103: 5-6.
9. Hu H, Pierce GN, Zhong G. The atherogenic effects of chlamydia are dependent on serum cholesterol and specific to Chlamydia pneumoniae. J Clin Invest 1999; 103: 747-53.
10. Saikku P, Leinonen M, Tenkanen L, Linnanmaki E, Ekman MR, Manninen V, et al. Chronic Chlamydia pneumoniae infection as a risk factor for coronary heart disease in the Helsinki Heart Study. Ann Intern Med 1992; 116:273-8.
11. Niessner A, Kaun C, Zorn G, Speidl W, Turel Z, Christiansen G, et al. Polymorphic membrane protein (PNT) 20 and PMP 21 of Chlamydia pneumoniae induce proinflammatory mediators in human endothelial cells in vitro by activation of the nuclear factor-kappaB pathway. J Infect Dis 2003; 188: 108-13.
12. Kol A, Sukhova GK, Lichtman AH, Libby P. Chlamydial heat shock protein 60 localizes in human atheroma and regulates macrophage tumor necrosis factor-alpha and matrix metalloproteinase expression. Circulation 1998; 98: 300-7.
13. Nurminen M, Leinonen M, Saikku P, Makela PH. The genus-specific antigen of Chlamydia: resemblance to the lipopolysaccharide of enteric bacteria. Science 1983; 220: 1279-81.
14. Dore MP, Sepulveda AR, Bacciu PP, Blasi F, Simula L, Marras L, et al. Detection of Chlamydiae pneumoniae but not Helicobacter pylori DNA in atherosclerosis plaques. Dig Dis Sci 2003; 48: 945-51.
15. Farsak B, Yildirir A, Akyon Y, Pinar A, Oc M, Boke E, et al. Detection of Chlamydia pneumoniae and Helicobacter pylori DNA in human atherosclerotic plaques by PCR. J Clin Microbiol 2000; 38: 4408-11.
16. Kaplan M, Yavuz SS, Cinar B, Koksal V, Kut MS, Yapici F, et al. Detection of Chlamydia pneumoniae and Helicobacter pylori in atherosclerotic plaques of carotid artery by polymerase chain reaction. Int J Infect Dis 2006; 10: 116-23.
17. Weiss TW, Kvakan H, Kaun C, Prager M, Speidl WS, Zorn G, et al. No evidence for a direct role of Helicobacter pylori and Mycoplasma pneumoniae in carotid artery atherosclerosis. J Clin Pathol 2006; 59: 1186-90.
18. Mach F, Sukhova GK, Michetti M, Libby P, Michetti P. Influence of Helicobacter pylori infection during atherogenesis in vivo in mice. Circ Res 2002; 90: E1-4.
19. Folsom AR, Nieto FJ, Sorlie P, Chambless LE, Graham DY. Helicobacter pylori seropositivity and coronary heart disease incidence. Atherosclerosis Risk In Communities (ARIC) Study Investigators. Circulation 1998; 98: 845-50.
20. Morgando A, Sanseverino P, Perotto C, Molino F, Gai V, Ponzetto A. Helicobacter pylori seropositivity in myocardial infarction. Lancet 1995; 345: 1380.
21. Strachan DP, Mendall MA, Carrington D, Butland BK, Yarnell JW, Sweetnam PM, et al. Relation of Helicobacter pylori infection to 13-year mortality and incident ischemic heart disease in the caerphilly prospective heart disease study. Circulation 1998; 98: 1286-90.
22. Wald NJ, Law MR, Morris JK, Bagnall AM. Helicobacter pylori infection and mortality from ischaemic heart disease: negative result from a large, prospective study. BMJ 1997; 315: 1199-201.
23. Pasceri V, Cammarota G, Patti G, Cuoco L, Gasbarrini A, Grillo RL, et al. Association of virulent Helicobacter pylori strains with ischemic heart disease. Circulation 1998; 97: 1675-9.
24. Pussinen PJ, Nyyssonen K, Alfthan G, Salonen R, Laukkanen JA, Salonen JT. Serum antibody levels to Actinobacillus actinomy-cetemcomitans predict the risk for coronary heart disease. Arterioscler Thromb Vasc Biol 2005; 25: 833-8.
25. Spahr A, Klein E, Khuseyinova N, Boeckh C, Muche R, Kunzec M, et al. Periodontal infections and coronary heart disease: role of periodontal bacteria and importance of total pathogen burden in the Coronary Event and Periodontal Disease (CORODONT) study. Arch Intern Med 2006; 166: 554-9.
26. Brodala N, Merricks EP, Bellinger DA, Damrongsri D, Offenbacher S, Beck J, et al. Porphyromonas gingivalis bacteremia induces coronary and aortic atherosclerosis in normocholesterolemic and hypercholesterolemic pigs. Arterioscler Thromb Vasc Biol 2005; 25: 1446-51.
27. Gibson FC, 3rd, Hong C, Chou HH, Yumoto H, Chen J, Lien E, et al. Innate immune recognition of invasive bacteria accelerates atherosclerosis in apolipoprotein E-deficient mice. Circulation 2004; 109: 2801-6.
28. Lalla E, Lamster IB, Hofmann MA, Bucciarelli L, Jerud AP, Tucker S, et al. Oral infection with a periodontal pathogen accelerates early atherosclerosis in apolipoprotein E-null mice. Arterioscler Thromb Vasc Biol 2003; 23: 1405-11.
29. Li L, Messas E, Batista EL Jr, Levine RA, Amar S. Porphyromonas gingivalis infection accelerates the progression of atherosclerosis in a heterozygous apolipoprotein E-deficient murine model. Circulation 2002; 105: 861-7.
30. DeStefano F, Anda RF, Kahn HS, Williamson DF, Russell CM. Dental disease and risk of coronary heart disease and mortality. Bmj 1993; 306: 688-91.
31. Hujoel PP, Drangsholt M, Spiekerman C, DeRouen TA. Periodontal disease and coronary heart disease risk. Jama 2000; 284: 1406-10.
32. Hsich E, Zhou YF, Paigen B, Johnson TM, Burnett MS, Epstein SE. Cytomegalovirus infection increases development of atherosclerosis in Apolipoprotein-E knockout mice. Atherosclerosis 2001; 156: 23-8.
33. Tabib A, Leroux C, Mornex JF, Loire R. Accelerated coronary atherosclerosis and arteriosclerosis in young human-immuno-deficiency-virus-positive patients. Coron Artery Dis 2000; 11: 41-6.
34. De Castro S, Migliau G, Silvestri A, D'Amati G, Giannantoni P, Cartoni D, et al. Heart involvement in AIDS: a prospective study during various stages of the disease. Eur Heart J 1992; 13: 1452-9.
35. Matetzky S, Domingo M, Kar S, Noc M, Shah PK, Kaul S, et al. Acute myocardial infarction in human immunodeficiency virus-infected patients. Arch Intern Med 2003; 163: 457-60.
36. Zhu J, Quyyumi AA, Norman JE, Csako G, Waclawiw MA, Shearer GM, et al. Effects of total pathogen burden on coronary artery disease risk and C-reactive protein levels. Am J Cardiol 2000; 85: 140-6.
37. Smeeth L, Thomas SL, Hall AJ, Hubbard R, Farrington P, Vallance P. Risk of myocardial infarction and stroke after acute infection or vaccination. N Engl J Med 2004; 351: 2611-8.
38. Binder CJ, Horkko S, Dewan A, Chang MY, Men EP, Goodyear CS, et al. Pneumococcal vaccination decreases atherosclerotic lesion formation: molecular mimicry between Streptococcus pneumoniae and oxidized LDL. Nat Med 2003; 9: 736-43.
39. Stemme S, Faber B, Holm J, Wiklund O, Witztum JL, Hansson GK. T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein. Proc Natl Acad Sci USA 1995; 92: 3893-7.
40. Kol A, Bourcier T, Lichtman AH, Libby P. Chlamydial and human heat shock protein 60s activate human vascular endothelium, smooth muscle cells, and macrophages. J Clin Invest 1999; 103: 571-7.
41. Edfeldt K, Swedenborg J, Hansson GK, Yan ZQ. Expression of toll-like receptors in human atherosclerotic lesions: a possible pathway for plaque activation. Circulation 2002; 105: 1158-61.
42. Xu XH, Shah PK, Faure E, Equils O, Thomas L, Fishbein MC, et al. Toll-like receptor-4 is expressed by macrophages in murine and human lipid-rich atherosclerotic plaques and upregulated by oxidized LDL. Circulation 2001; 104: 3103-8.
43. Faure E, Thomas L, Xu H, Medvedey A, Equils O, Arditi M. Bacterial lipopolysaccharide and IFN-gamma induce Toll-like receptor 2 and Toll-like receptor 4 expression in human endothelial cells: role of NF-kappa B activation. J Immunol 2001; 166: 2018-24.
44. Zeuke S, Ulmer AJ, Kusumoto S, Katus HA, Heine H. TLR4-mediated inflammatory activation of human coronary artery endothelial cells by LPS. Cardiovasc Res 2002; 56: 126-34.
45. Wiedermann CJ, Kiechl S, Dunzendorfer S, Schratzberger P, Egger G, Oberhollenzer F, et al. Association of endotoxemia with carotid atherosclerosis and cardiovascular disease: prospective results from the Bruneck Study. J Am Coll Cardiol 1999; 34: 1975-81.
46. Mullick AE, Tobias PS, Curtiss LK. Modulation of atherosclerosis in mice by Toll-like receptor 2. J Clin Invest 2005; 115: 3149-56.
47. Michelsen KS, Wong MH, Shah PK, Zhang W, Yano J, Doherty TM, et al. Lack of Toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E. Proc Natl Acad Sci USA 2004; 101: 10679-84.
48. Sato K, Niessner A, Kopecky SL, Frye RL, Goronzy JJ, Weyand CM. TRAIL-expressing T cells induce apoptosis of vascular smooth muscle cells in the atherosclerotic plaque. J Exp Med 2006; 203: 239-50.
49. Niculescu F, Rus H. The role of complement activation in atherosclerosis. Immunol Res 2004; 30: 73-80.
50. Niculescu F, Rus H. Complement activation and atherosclerosis. Mol Immunol 1999; 36: 949-55.
51. Speidl WS, Exner M, Amighi J, Kasd SP, Zorn G, Maurer G, et al. Complement component C5a predicts future cardiovascular events in patients with advanced atherosclerosis. Eur Heart J 2005; 26: 2294-9.
52. Zhang X, Niessner A, Nakajima T, Ma-Krupa W, Kopecky SL, Frye RL, et al. Interleukin 12 Induces T-Cell Recruitment Into the Atherosclerotic Plaque. Circ Res 2006; 98: 524-31.
53. Paulsson G, Zhou X, Tornquist E, Hansson GK. Oligoclonal T cell expansions in atherosclerotic lesions of apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2000; 20: 10-7.
54. Liuzzo G, Goronzy JJ, Yang H, Kopecky SL, Hohnes DR, Frye RL, et al. Monoclonal T-cell proliferation and plaque instability in acute coronary syndromes. Circulation 2000; 101: 2883-8.
55. Zhou X, Robertson AK, Hjerpe C, Hansson GK. Adoptive transfer of CD4+ T cells reactive to modified low-density lipoprotein aggravates atherosclerosis. Arterioscler Thromb Vasc Biol 2006; 26 864-70.
56. Liuzzo G, Kopecky SL, Frye RL, O'Fallon WM, Maseri A, Goronzy JJ, et al. Perturbation of the T-cell repertoire in patients with unstable angina. Circulation 1999; 100: 2135-9.
57. Nakajima T, Schulte S, Warrington KJ, Kopecky SL, Frye RL, Goronzy JJ, et al. T-cell-mediated lysis of endothelial cells in acute coronary syndromes. Circulation 2002; 105: 570-5.
58. Nakajima T, Goek O, Zhang X, Kopecky SL, Frye RL, Goronzy JJ, et al. De novo expression of killer immunoglobulin-like receptors and signaling proteins regulates the cytotoxic function of CD4 T cells in acute coronary syndromes. Circ Res 2003; 93: 106-13.
59. Pryshchep S, Sato K, Goronzy JJ, Weyand CM. T cell recognition and killing of vascular smooth muscle cells in acute coronary syndrome. Circ Res 2006; 98: 1168-76.
60. Goronzy JJ, Weyand CM. Immunosuppression in atherosclerosis: mobilizing the opposition within. Circulation 2006; 114: 1901-4.
61. Ait-Oufella H, Salomon BL, Potteaux S, Robertson AK, Gourdy P, Zoll J, et al. Natural regulatory T cells control the development of atherosclerosis in mice. Nat Med 2006; 12: 178-80.
62. Fredrikson GN, Hedblad B, Berglund G, Alm R, Nilsson JA, Schiopu A, et al. Association between IgM against an aldehyde-modified peptide in apolipoprotein B-100 and progression of carotid disease. Stroke 2007; 38: 1495-500.
63. Hulthe J, Bokemark L, Fagerberg B. Antibodies to oxidized LDL in relation to intima-media thickness in carotid and femoral arteries in 58-year-old subjectively clinically healthy men. Arterioscler Thromb Vasc Biol 2001; 21: 101-7.
64. Steffens S, Burger F, Pelli G, Dean Y, Elson G, Kosco-Vilbois M, et al. Short-term treatment with anti-CD3 antibody reduces the development and progression of atherosclerosis in mice. Circulation 2006; 114: 1977-84.
65. Boyle JJ, Weissberg PL, Bennett MR. Tumor necrosis factor-alpha promotes macrophage-induced vascular smooth muscle cell apoptosis by direct and autocrine mechanisms. Arterioscler Thromb Vasc Biol 2003; 23: 1553-8.
66. Niemann-Jonsson A, Ares MP, Yan ZQ, Bu DX, Fredrikson GN, Branen L, et al. Increased rate of apoptosis in intimal arterial smooth muscle cells through endogenous activation of TNF receptors. Arterioscler Thromb, Vasc Biol 2001; 21: 1909-14.
67. Galis ZS, Sukhova GK, Lark MW, Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 1994; 94: 2493-503.
68. Blankenberg S, Rupprecht HJ, Poirier O, Bickel C, Smieja M, Hafner G, et al. Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation 2003; 107: 1579-85.
69. Niebauer J, Hambrecht R, Velich T, Hauer K, Marburger C, Kalberer B, et al. Attenuated progression of coronary artery disease after 6 years of multifactorial risk intervention: role of physical exercise. Circulation 1997; 96: 2534-41.
70. Fantuzzi G. Adipose tissue, adipokines, and inflammation. J Allergy Clin Immunol 2005; 115: 911-19; quiz 920.
71. Paffenbarger RS Jr, Hyde RT, Wing AL, Lee IM, Jung DL, Kampert JB. The association of changes in physical-activity level and other lifestyle characteristics with mortality among men. N Engl J Med 1993; 328: 538-45.
72. Gielen S, Walther C, Schuler G, Hambrecht R. Anti-inflammatory effects of physical exercise. A new mechanism to explain the benefits of cardiac rehabilitation? J Cardiopulm Rehabil 2005; 25: 339-42.
73. Smith JK, Dykes R, Douglas JE, Krishnaswamy G, Berk S. Longterm exercise and atherogenic activity of blood mononuclear cells in persons at risk of developing ischemic heart disease. JAMA 1999; 281: 1722-7.
74. Niessner A, Richter B, Penka M, Steiner S, Strasser B, Ziegler S, et al. Endurance training reduces circulating inflammatory markers in persons at risk of coronary events: impact on plaque stabilization? Atherosclerosis 2006; 186: 160-5.
75. Milani RV, Lavie CJ, Mehra MR. Reduction in C-reactive protein through cardiac rehabilitation and exercise training. J Am Coll Cardiol 2004; 43: 1056-61.
76. Methe H, Kim JO, Kofler S, Nabauer M, Weis M. Statins decrease Toll-like receptor 4 expression and downstream signaling in human CD14+ monocytcs. Arterioscler Thromb Vase Biol 2005; 25: 1439-45.
77. Niessner A, Steiner S, Speidl WS, Pleiner J, Seidinger D, Maurer G, et al. Simvastatin suppresses endotoxin-induced upregulation of toll-like receptors 4 and 2 in vivo. Atherosclerosis 2006; 189: 408-13.
78. Goldman F, Hohl RJ, Crabtree J, Lewis-Tibesar K, Koretzky G. Lovastatin inhibits T-cell antigen receptor signaling independent of its effects on ras. Blood 1996; 88: 4611-9.
79. Kwak B, Mulhaupt F, Myit S, Mach F. Statins as a newly recögnized type of immunomodulator. Nat Med 2000; 6: 1399-402.
80. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352: 1425-35.
81. Mason RP, Walter MF, Jacob RF. Effects of HMG-CoA reductase inhibitors on endothelial function: role of microdomains and oxidative stress. Circulation 2004; 109(21 Suppl 1): 1134-41.
82. Hillyard DZ, Cameron AJ, McDonald KJ, Thomson J, MacIntyre A, Shiels PG, et al. Simvastatin inhibits lymphocyte function in normal subjects and patients with cardiovascular disease. Atherosclerosis 2004; 175: 305-13.
83. Mora S, Ridker PM. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) - can C-reactive protein be used to target statin therapy in primary prevention? Am J Cardiol 2006; 97(2A): 33A-41A.
84. Diet F, Pratt RE, Berry GJ, Momose N, Gibbons GH, Dzau VJ. Increased accumulation of tissue ACE in human atherosclerotic coronary artery disease. Circulation 1996; 94: 2756-67.
85. Schieffer B, Schieffer E, Hilfiker-Kleiner D, Hilfiker A, Kovanen PT, Kaartinen M, et al. Expression of angiotensin II and interleukin 6 in human coronary atherosclerotic plaques: potential implications for inflammation and plaque instability. Circulation 2000; 101: 1372-8.
86. Peeters AC, Netea MG, Kullberg BJ, Thien T, van der Meer JW. The effect of renin-angiotensin system inhibitors on pro- and anti-inflammatory cytokine production. Immunology 1998; 94: 376-9.
87. Fukuzawa M, Satoh J, Sagara M, Muto G, Muto Y, Nishimura S, et al. Angiotensin converting enzyme inhibitors suppress production of tumor necrosis factor-alpha in vitro and in vivo. Immunopharmacology 1997; 36:49-55.
88. Pasceri V, Wu HD, Willerson JT, Yeh ET. Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-gamma activators. Circulation 2000; 101: 235-8.
89. Haffner SM, Greenberg AS, Weston WM, Chen H, Williams K, Freed MI. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 2002; 106: 679-84.
90. Meadows TA, Bhatt DL. Clinical aspects of platelet inhibitors and thrombus formation. Circ Res 2007; 100: 1261-75.
91. Prasad K. C-reactive protein (CRP)-lowering agents. Cardiovasc Drug Rev 2006; 24: 33-50.
92. Gupta S, Leatharn EW, Carrington D, Mendall MA, Kaski JC, Camm AJ. Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction. Circulation 1997; 96: 404-7.
93. Gurfinkel E, Bozovich G, Daroca A, Beek E, Mautner B. Randomised trial of roxithromycin in non-Q-wave coronary syndromes: ROXIS Pilot Study. ROXIS Study Group. Lancet 1997; 350: 404-7.
94. Cannon CP, Braunwald E, McCabe CH, Grayston JT, Muhlestein B, Giugliano RP, et al. Antibiotic treatment of Chlamydia pneumoniae after acute coronary syndrome. N Engl J Med 2005; 352: 1646-54.
95. Cercek B, Shah PK, Noc M, Zahger D, Zeymer U, Matetzky S, et al. Effect of short-term treatment with azithromycin on recurrent ischaemic events in patients with acute coronary syndrome in the Azithromycin in Acute Coronary Syndrome (AZACS) trial: a randomised controlled trial. Lancet 2003; 361: 809-13.
96. Grayston JT, Kronmal RA, Jackson LA, Parisi AF, Muhlestein JB, Cohen JD, et al. Azithromycin for the secondary prevention of coronary events. N Engl J Med 2005; 352: 1637-45.
97. O'Connor CM, Dunne MW, Pfeffer MA, Muhlestein JB, Yao L, Gupta S, et al. Azithromycin for the secondary prevention of coronary heart disease events: the WIZARD study: a randomized controlled trial. JAMA 2003; 290: 1459-66.
98. Gieffers J, Fullgraf H, Jahn J, Klinger M, Dalhoff K, Katus HA, et al. Chlamydia pneumoniae infection in circulating human monocytes is refractory to antibiotic treatment. Circulation 2001; 103: 351-6.
99. Elizalde JI, Perez-Pujol S, Heras M, Sionis A, Casanovas N, Martorell T, et al. Effects of Helicobacter pylori eradication on platelet activation and disease recurrence in patients with acute coronary syndromes. Helicobacter 2004; 9: 681-9.
100. Madan M, Bishayi B, Hoge M, Messas E, Amar S. Doxycycline affects diet- and bacteria-associated atherosclerosis in an ApoE heterozygote murine model: cytokine profiling implications. Atherosclerosis 2007; 190: 62-72.
101. Brown DL, Desai KK, Vakili BA, Nouneh C, Lee HM, Golub LM. Clinical and biochemical results of the metalloproteinase inhibition with subantimicrobial doses of doxycycline to prevent acute coronary syndromes (MIDAS) pilot trial. Arterioscler Thromb Vasc Biol 2004; 24: 733-8.
102. Peterson JT. The importance of estimating the therapeutic index in the development of matrix metalloproteinase inhibitors. Cardinvasc Res 2006; 69: 677-87.
103. Paju S, Sinisalo J, Pussinen PJ, Valtonen V, Nieminen MS. Is periodontal infection behind the failure of antibiotics to prevent coronary events? Atherosclerosis 2006; 193: 193-5.
104. Etter JR, Hinderliter AL, Offenbacher S, Beek JD, Caughey M, Brodala N, et al. The effects of periodontal therapy on vascular endothelial function: a pilot trial. Am Heart J 2006; 151: 47.
105. Henry K, Melroe H, Ruebsch J, Hermundson J, Levine C, Swensen L, et al. Severe premature coronary artery disease with protease inhibitors. Lancet 1998; 351(9112): 1328.
106. Naghavi M, Barlas Z, Siadaty S, Naguib S, Madjid M, Casscells W. Association of influenza vaccination and reduced risk of recurrent myocardial infarction. Circulation 2000; 102: 3039-45.
107. Nichol KL, Nordin J, Mullooly J, Lask R, Fillbrandt K, Iwane M. influenza vaccination and reduction in hospitalizations for cardiac disease and stroke among the elderly. N Engl J Med 2003; 348: 1322-32.
108. Siscovick DS, Raghunathan TE, Lin D, Weinmnann S, Arbogast P, Lemaitre RN, et al. Influenza vaccination and the risk of primary cardiac arrest. Am J Epidemiol 2000; 152: 674-7.
109. Gurfinkel EP, de la Fuente RL, Mendiz O, Mautner B. Influenza vaccine pilot study in acute coronary syndromes and planned percutaneous coronary interventions: the FLU Vaccination Acute Coronary Syndromes (FLUVACS) Study. Circulation 2002; 105: 2143-7.
110. Jackson LA, Yu O, Heckbert SR, Psaty BM, Malais D, Barlow WE, et al. Influenza vaccination is not associated with a reduction in the risk of recurrent coronary events. Am J Epidemiol 2002; 156: 634-40.
111. Ameli S, Hultgardh-Nilsson A, Regnstrom J, Calara F, Yano J, Cercek B, et al. Effect of immunization with homologous LDL and oxidized LDL on early atherosclerosis in hypercholesterolemic rabbits. Arterioscler Thromb Vasc Biol 1996; 16: 1074-9.
112. Freigang S, Horkko S, Miller E, Witztum JL, Palinski W. Immunization of LDL receptor-deficient mice with homologous malondialdehyde-modified and native LDL reduces progression of atherosclerosis by mechanisms other than induction of high titers of antibodies to oxidative neoepitopes. Arterioscler Thromb Vasc Biol 1998; 18: 1972-82.
113. Nilsson J, Calara F, Regnstrom J, Hultgardh-Nilsson A, Ameli S, Cercek B, et al. Immunization with homologous oxidized low density lipoprotein reduces neointimal formation after balloon injury in hypercholesterolemic rabbits. J Am Coll Cardiol 1997; 30: 1886-91.
114. Palinski W, Miller E, Witzum JL. Immunization of low density lipoprotein (LDL) receptor-deficient rabbits with homologous malondialdehyde-modified LDL reduces atherogenesis. Proc Natl Acad Sci USA 1995; 92: 821-5.
115. Zhou X, Caligiuri G,Hamsten A, Lefvert AK, Hansson GK. LDL immunization induces T-cell-dependent antibody formation and protection against atherosclerosis. Arterioscler Thromb Vasc Biol 2001; 21: 108-14.
116. van Puijvelde GH, Hauer AD, de Vos P, van den Heuvel R, van Herwijnen MJ, van der Zee R, et al. Induction of oral tolerance to oxidized low-density lipoprotein ameliorates atherosclerosis. Circulation 2006; 114: 1968-76.
117. Xu Q, Willeit J, Marosi M, Kleindienst R, Oberhollenzer F, Kiechl S, et al. Association of serum antibodies to heat-shock protein 65 with carotid atherosclerosis. Lancet 1993; 341: 255-9.
118. Harats D, Yacov N, Gilburd B, Shoenfeld Y, George J. Oral tolerance with heat shock protein 65 attenuates Mycobacterium tuberculosis-induced and high-fat-diet-driven atherosclerotic lesions. J Am Coll Cardiol 2002; 40: 1333-8.
119. Maron R, Sukhova G, Faria AM, Hoffmann E, Mach F, Libby P, et al. Mucosal administration of heat shock protein-65 decreases atherosclerosis and inflammation in aortic arch of low-density lipoprotein receptor-deficient mice. Circulation 2002; 106: 1708-15.
120. Nilsson J, Hansson GK, Shah PK. Immunomodulation of atherosclerosis: implications for vaccine development. Arterioscler Thromb Vasc Biol 2005; 25: 18-28.
121. Kovaiou RD, Herndler-Brandstetter D, Grubeck-Loebenstein B. Age-related changes in immunity: implications for vaccination in the elderly. Expert Rev Mol Med 2007; 9: 1-17.
122. Dall JL, Peel A.A. A trial of hydrocartisone in acute myocardial infarction. Lancet 1963; 121097-8.
123. Gerisch RA, Compeau L. Treatment of acute myocardial infarction in man with cortisone. Am J Cardiol 1958-1: 535-6.
124. Makheja AN, Bloom S, Muesing R, Simon T, Bailey JM. Anti-inflammatory drugs in experimental atherosclerosis. 7. Spontaneous atherosclerosis in WHHL rabbits and inhibition by cortisone acetate. Atherosclerosis 1989; 76: 155-61.
125. Maclean D, Fishbein MC, Braunwald E, Maroko PR. Long-term preservation of ischemic myocardium after experimental coronary artery occlusion. J Clin Invest 1978; 61: 541-51.
126. Skyschally A, Haude M, Dorge H, Thielmann M, Duschin A, van de Sand A, et al. Glucocorticoid treatment prevents progressive myocardial dysfunction resulting from experimental coronary microembolization. Circulation 2004; 109: 2337-42.
127. Barzilai D, Plavnick J, Hazani A, Einath R, Kleinhaus N, Kanter Y. Use of hydrocortisone in the treatment of acute myocardial infarction. Summary of a clinical trial in 446 patients. Chest 1972; 61: 488-91.
128. Bulkley BH, Roberts WC. Steroid therapy during acute myocardial infarction. A cause of delayed healing and of ventricular aneurysm. Am J Med 1974; 56: 244-50.
129. Roberts R, DeMello V, Sobel BE. Deleterious effects of methyl- prednisolone in patients with myocardial infraction. Circulation 1976; 53(3 Suppl): 1204-6.
130. Waksman R, Pakala R, Burnett MS, Gulick CP, Leborgne L, Fournadjiev J, et al. Oral rapamycin inhibits growth of atherosclerotic plaque in apoE knock-out mice. Cardiovasc Radiat Med 2003; 4: 34-8.
131. Miller LW. Cardiovascular toxicities of immunosuppressive agents. Am J Transplant 2002; 2: 807-18.
132. Maisel WH. Unanswered questions-drug-eluting stents and the risk of late thrombosis. N Engl J Med 2007; 356: 981-4.
133. Smith SC Jr, Feldman TE, Hirshfeld JW Jr, Jacobs AK, Kern MJ, King SB 3rd, et al. ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention-summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). Circulation 2006; 113: 156-75.
134. Vakeva AP, Agah A, Rollins SA, Matis LA, Li L, Stahl GL. Myocardial infarction and apoptosis after myocardial ischemia and reperfusion: role of the terminal complement components and inbibition by anti-C5 therapy. Circulation 1998; 97: 2259-67.
135. Mahaffey KW, Granger CB, Nicolau JC, Ruzyllo W, Weaver WD, Theroux P, et al. Effect of pexelizumab, an anti-C5 complement intibody, as adjunctive therapy to fibrinolysis in acute myocardial infarction the COMPlement inhibition in myocardial infarction treated with thromboLYtics (COMPLY) trial. Circulation 2003; 108: 1176-83.
136. Armstrong PW, Granger CB, Adams PX, Hamm C, Holmes D Jr, O'Neill WW, et al. Pexelizumab for acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention: a randomized controlled trial. JAMA 2007; 297: 43-51.
137. Haverich A, Sheman SK, Levy JH, Chen JC, Carrier M, Taylor KM, et al. Pexelizurnab reduces death and myocardial infarction in higher risk cardiac surgical patients. Ann Thorac Surg 2006; 82: 486-92.
138. Schmidt C. Toll-like receptor therapies compete to reduce side effects. Nat Biotechnol. 2006; 24: 20-1.
139. Hawkins LD, Christ WJ, Rossignol DP. Inhibition of endotoxin response by synthetic TLR4 antagonists. Curr Top Med Chem 2004; 4: 1147-71.
140. Branen L, Hovgaard L, Nitulescu M, Bengtsson E, Nilsson J, Jovinge S. Inhibition of tumor necrosis factor-alpha reduces atherosclerosis in apolipoprotein E knockout mice. Artenoscler Thromb Vasc Biol 2004; 24: 2137-42.
141. Rizzello V, LiuzzonG BrugalettaS,Re-buzziA, Biasucci,Crea F. Modulation of CD4(+)CD28null T lymphocytes by tumor necrosis factor-alpha blockade in patients with unstable angina. Circulation 2006; 113: 2272-7.
142. Bozkurt B, Torre-Amione G, Warren MS, Whitmore J, Soran OZ, Feldman AM, et al. Results of targeted anti-tumor necrosis factor therapy with etanercept (ENBREL) in patients with advanced heart failure. Circulation 2001; 103: 1044-7.
143. Mann DL. Inflammatory mediators and the failing heart: past, present, and the foreseeable future. Circ Res 2002; 91: 988-98.
144. Hansen PR, Chew M, Zhou J, Daugherty A, Heegaard N, Jensen P, et al. Freunds adjuvant alone is antiatherogenic in apoE-deficient mice and specific immunization against TNFalpha confers no additional benefit. Atherosclerosis 2001; 158: 87-94.
145. Irace C, Mancuso G, Fiaschi E, Madia A, Sesti G, Gnasso A. Effect of anti TNFalpha therapy on arterial diameter and wall shear stress and HDL cholesterol. Atherosclerosis 2004; 177: 113-8.
146. Mach F, Schonbeck U, Sukhova GK, Atkinson E, Libby P. Reduction of atherosclerosis in mice by inhibition of CD40 signalling. Nature 1998; 394: 200-3.
147. Danese S, Fiocchi C. Platelet activation and the CD40/CD40 ligand pathway: mechanisms and implications for human disease. Crit Rev Immunol 2005; 25: 103-121.
148. Ishii KJ, Uematsu S, Akira S. 'Toll' gates for future immunotherapy. Curr Pharm Des 2006; 12(32): 4135-42.
149. Kraaijeveld AO, de lager SC, van Berkel TJ, Biessen EA, Jukema Chemokines and atherosclerotic plaque progression: towards therapeutic targeting? Curr Pharm Des 2007; 13(10): 1039-52.
150. Stoll LL, Denning GM, Weintraub NL. Endotoxin, TLR4 signaling and vascular inflammation: potential therapeutic targets in cardiovascular disease. Curr Pharm Des 2006; 12(32): 4229-45.